Knockout and suppression therapies designed for LEF1 have been shown to be effective in reducing tumor growth, migration, and invasion of CLL, CRC, glioblastoma multiforme (GBM), and renal cell carcinoma (RCC) [40]. Here, LEF1 is linked to B-cell chronic lymphocytic leukemia.